The discontinuation rate due to poor performance status was significantly higher in the high-CRP group (<i>p</i> < 0.001).<h4>Conclusion</h4>A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment. Here, CRP is linked to hepatocellular carcinoma.